MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyag247

Медицинская библиотека · The oncologist · 2026

Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study.

Li Bohan, Luo Chengjuan, Lu Jun, Cai Jiaoyang, Zhu Yiping, Li Chi-Kong, Guo Ye, Jiang Hua, Huang Xiaohang, Cheng Yifei, Pan Jing, Sun Zimin, Feng Xiaoqin, Liu Xuan, Chen Kai, Yu Jie, He Guangcui, Wang Jingbo, Liu Aiguo, Wu Xiaoyan, Wan Liping, Wang Hongmei, Xiao Xia, Qin Maoquan, Pan KaiLi, Lu Jing, Xiao Peifang, Chen Jing, Sun Ruijuan, Hu Shaoyan

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Hematopoietic stem cell transplantation (HSCT) is a curable treatment for refractory/relapse B-cell acute lymphoblastic leukemia (R/R B-ALL).Traditional chemotherapy or Chimeric antigen receptor T-cell (CAR-T) therapy are both important methods to achieve MRD negativity before HSCT. However, which treatment is preferred needs to be clarified.

PATIENTS AND

METHODS

In this study, 269.

PATIENT: s with R/R B-ALL who underwent allo-HSCT after CAR-T cell therapy (CAR-T, n = 142) or chemotherapy (CT, n = 127) were enrolled from multicenters.

RESULTS

The 3-year overall survival (OS) after transplantation was 66.8% in the CAR-T group and 72.3% in the chemotherapy (CT) group. The 3-year relapse-free survival (RFS) was 65.3% in the CAR-T group and 65.9% in the CT group. The 3-year graft-versus-host disease, relapse-free survival (GRFS) and cumulative incidence of relapse (CIR) were also similar between the two groups. Among patients who achieved first complete remission (CR1) before transplantation, the proportion receiving chemotherapy was significantly higher than that receiving CAR-T therapy (37.5% vs. 13.6%; P < 0.001). In this CR1 subgroup, the CT group demonstrated superior outcomes, including improved OS, RFS, and GRFS.

CONCLUSION

In pediatric R/R B-ALL, CAR-T bridging to HSCT appears to yield post-transplant survival comparable to chemotherapy, though a higher rate of moderate to severe chronic GVHD was observed. CAR-T may be a reasonable option, but closer GVHD monitoring seems warranted.

Для цитирования: Li Bohan, Luo Chengjuan, Lu Jun, Cai Jiaoyang, Zhu Yiping, Li Chi-Kong, Guo Ye, Jiang Hua, Huang Xiaohang, Cheng Yifei, Pan Jing, Sun Zimin, Feng Xiaoqin, Liu Xuan, Chen Kai, Yu Jie, He Guangcui, Wang Jingbo, Liu Aiguo, Wu Xiaoyan, Wan Liping, Wang Hongmei, Xiao Xia, Qin Maoquan, Pan KaiLi, Lu Jing, Xiao Peifang, Chen Jing, Sun Ruijuan, Hu Shaoyan. Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study.. The oncologist. 2026. DOI: 10.1093/oncolo/oyag247.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.